Speakers
Alexander Ploss
Associate Professor of Molecular Biology
Princeton University
Day One
Tuesday April 26, 2022
2:30 pm | Utility of Animal Models for Evaluating Preclinically Novel HBV Therapeutics
Andrew Vaillant
Chief Scientific Officer
Replicor
Day Two
Wednesday April 27, 2022
9:00 am | Surface Antigen Loss & Transaminase Flares – Critical Milestones for Achieving Functional Cure
Bertrand Georges
Chief Technology Officer
Altimmune
Day Two
Wednesday April 27, 2022
2:00 pm | HepTcell as Immunotherapy to Achieve Functional Cure for Chronic HBV
8:30 am | Panel Discussion: Defining Clinical Endpoints & Exploring Surrogates for HBV Functional Cure
Carey Hwang
Senior Vice President, Clinical Research, Head of Chronic Infection
Vir Biotechnology
Day One
Tuesday April 26, 2022
11:30 am | The Potential Role of an Anti-HBs Antibody in Combination Therapy to Achieve Functional Cure in Chronic HBV
8:30 am | Panel Discussion: What, When & How? Pursuing Combination Therapy to Improve Durable Efficacy & Decrease Viral Breakthrough
Chari Cohen
Senior Vice President
Hepatitis B Foundation
Day One
Tuesday April 26, 2022
4:30 pm | Developing Patient-Focused Clinical Trials to Ensure Recruitment, Improve Access, and Promote Diversity
Christy Hebner
Vice President, Virology & Chief Operations Officer, Research
Vir Biotechnology
Day One
Tuesday April 26, 2022
5:00 pm | Chair’s Closing Remarks
8:25 am | Chair’s Opening Remarks
David Anderson
Chief Scientific Officer
VBI Vaccines
Day One
Tuesday April 26, 2022
11:00 am | Clinical Trial Design Considerations for a Combination Therapy with Multiple Mechanisms of Action to Achieve a Functional Cure
8:30 am | Panel Discussion: What, When & How? Pursuing Combination Therapy to Improve Durable Efficacy & Decrease Viral Breakthrough
Day Two
Wednesday April 27, 2022
4:30 pm | Chair’s Closing Remarks & End of Conference
8:25 am | Chair’s Opening Remarks
Francisco Diaz- Mitoma
Chief Medical Officer
VBI Vaccines
Day Two
Wednesday April 27, 2022
8:30 am | Panel Discussion: Defining Clinical Endpoints & Exploring Surrogates for HBV Functional Cure
Herbert Virgin
Chief Scientific Officer & Executive Vice President of Research
Vir Biotechnology
Hubert Trübel
Chief Medical Officer
AiCuris
Day One
Tuesday April 26, 2022
3:30 pm | Translation of Antivirals & Immunostimulants in HBV: From Bench to Bedside
Jeysen Yogaratnam
Chief Medical Officer
Drug Farm
Day Two
Wednesday April 27, 2022
11:00 am | Exploring Immunotherapies in Development to Achieve a Functional Cure for Chronic HBV
Katherine Squires
Director, Research & Development
Antios Therapeutics
Day Two
Wednesday April 27, 2022
3:30 pm | Active Site Polymerase Inhibitor Nucleotides (ASPINs) for Chronic Hepatitis B Infection
Katie Kitrinos
Vice President, Clinical Virology
Assembly Biosciences
Day One
Tuesday April 26, 2022
1:30 pm | From HBV RNA to Core-Related Antigen: Novel Viral Biomarkers to Guide Treatment Management & Clinical Outcome Prediction
Day Two
Wednesday April 27, 2022
8:30 am | Panel Discussion: Defining Clinical Endpoints & Exploring Surrogates for HBV Functional Cure
Kees Melief
Chief Scientific Officer
ISA Pharmaceuticals
Day Two
Wednesday April 27, 2022
1:30 pm | Achieving Sustained Treatment Response: The Need for Immunotherapy in Chronic HBV
Linong Zhang
Director
Sanofi Pasteur
Luisa Stamm
Chief Medical Officer
Assembly Biosciences
Day One
Tuesday April 26, 2022
9:00 am | Interrogating Therapeutic Agents with Additive or Synergistic Activity against HBV for Combination Therapy
8:30 am | Panel Discussion: What, When & How? Pursuing Combination Therapy to Improve Durable Efficacy & Decrease Viral Breakthrough
Mark Dybul
Chief Executive Officer
Enochian BioSciences
Day Two
Wednesday April 27, 2022
9:30 am | Eliminating HBV for Sterilizing Cure: Is it Possible?
8:30 am | Panel Discussion: Defining Clinical Endpoints & Exploring Surrogates for HBV Functional Cure
Martin Leivers
Senior Director, Early Development Leader
GSK
Day One
Tuesday April 26, 2022
12:00 pm | Approaches for Direct Reduction of the Immunosuppressive HBs Antigen: Current Status & Outlook
8:30 am | Panel Discussion: What, When & How? Pursuing Combination Therapy to Improve Durable Efficacy & Decrease Viral Breakthrough
Michael Kishko
Principal Scientist, Global Antigen Design
Sanofi
Michael Newman
Founder & Chief Scientific Officer
Indaptus Therapeutics
Day Two
Wednesday April 27, 2022
12:00 pm | Driving Pre-Clinical Anti-HBV Activity With a Novel Multi-TLR Agonist Therapeutic Vaccine
Nezam Afdhal
Chief of the Division of Gastroenterology, Hepatology & Nutrition
Beth Israel Deaconess Medical Center
Day One
Tuesday April 26, 2022
9:30 am | Drawing Comparisons with Hepatitis C: Breaking New Ground or Following in the Footsteps?
Patrick Kennedy
Clinical Professor of Translational Hepatology
Queen Mary University Of London
Day One
Tuesday April 26, 2022
4:00 pm | Rethinking Treatment Thresholds & Patient Subgroups to Implement Targeted Clinical Trials
Day Two
Wednesday April 27, 2022
8:30 am | Panel Discussion: Defining Clinical Endpoints & Exploring Surrogates for HBV Functional Cure
Rajan George
Founder, President & Chief Executive Officer
Akshaya Bio
Day Two
Wednesday April 27, 2022
4:00 pm | Chimigen® HBV: An Immunotherapy for Chronic Hepatitis B
Shihyun You
Senior Scientific Director
GSK
Day Two
Wednesday April 27, 2022
11:30 am | Bepirovirsen Phase 2a Clinical Data Implying Potential Dual Mechanism of Action
Thomas Baumert
Professor of Medicine, Head Inserm Research Institute, Chair
Hepatology University Hospital
Timothy Block
President
Hepatitis B Foundation
Day One
Tuesday April 26, 2022
2:00 pm | Emerging & Established Non-Invasive Biomarkers for Predicting & Evaluating Efficacy of HBV Therapeutics
Ventzislav Vassilev
Senior Director, Vaccine Development Lead
GSK
Day Two
Wednesday April 27, 2022